4//SEC Filing
ARIAD PHARMACEUTICALS INC 4
Accession 0001127602-16-039308
CIK 0000884731operating
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 4:39 PM ET
Size
8.9 KB
Accession
0001127602-16-039308
Insider Transaction Report
Form 4
Haluska Frank
VP, Clinical R&D, CMO
Transactions
- Sale
Common Stock
2016-02-01$4.81/sh−16,133$77,587→ 135,424 total - Exercise/Conversion
Common Stock
2016-02-01+29,333→ 151,557 total - Exercise/Conversion
Restricted Stock Units
2016-02-01−29,333→ 29,333 totalExp: 2024-01-31→ Common Stock (29,333 underlying)
Footnotes (5)
- [F1]Shares were acquired upon vesting of restricted stock units awarded on January 31, 2014.
- [F2]Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $4.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- [F4]Each restricted stock unit represents a right to receive one share of ARIAD common stock.
- [F5]The restricted stock units vest as to one-third of the units on each of the first, second and third anniversaries of the date of the award (January 31,2014).
Documents
Issuer
ARIAD PHARMACEUTICALS INC
CIK 0000884731
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000884731
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 4:39 PM ET
- Size
- 8.9 KB